Marcel Filart, MD
Geriatric Medicine · Los Angeles, CANPI 1396775474
Payments from drug & device makers
Across 102 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$763
- Sunovion Pharmaceuticals Inc.$258
- Amgen$190
- AbbVie$178
- Lilly USA, LLC$155
- Sumitomo Pharma America, Inc.$129
- plus $658 from 19 others
What the payments were for
- Food & beverage$2,23996%
- Education$914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 28 | $763 |
| Sunovion Pharmaceuticals Inc. | 16 | $258 |
| Amgen | 7 | $190 |
| AbbVie | 8 | $178 |
| Lilly USA, LLC | 2 | $155 |
| Sumitomo Pharma America, Inc. | 8 | $129 |
| Xeris Pharmaceuticals, Inc. | 4 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Alkermes, Inc. | 3 | $66 |
| Novo Nordisk | 2 | $47 |
| Abbott | 2 | $46 |
| Biogen | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Novartis | 2 | $41 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| Johnson & Johnson | 1 | $25 |
| Viiv Healthcare Company | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| GSK | 1 | $20 |
| Insightec,inc | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$120
How this compares
$2,331 in reported general payments places this provider in the 85th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 65 | $335,997 |
| Invega HafyeraPaliperidone Palmitate | 14 | $298,658 |
| EliquisApixaban | 959 | $292,301 |
| JanuviaSitagliptin Phosphate | 493 | $215,010 |
| JardianceEmpagliflozin | 371 | $149,046 |
| AustedoDeutetrabenazine | 31 | $135,827 |
| XifaxanRifaximin | 106 | $121,650 |
| OzempicSemaglutide | 107 | $106,574 |
| LinzessLinaclotide | 162 | $93,129 |
| JulucaDolutegravir/Rilpivirine | 31 | $71,293 |
| NuplazidPimavanserin Tartrate | 21 | $70,235 |
| Invega SustennaPaliperidone Palmitate | 25 | $68,143 |
| XareltoRivaroxaban | 209 | $65,107 |
| Austedo XrDeutetrabenazine | 18 | $61,328 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $44,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $20 | $222,056514 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $763 | $197,15549 claims |
| Novo NordiskOzempic, Rybelsus | $47 | $138,551136 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $25 | $133,250234 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $11 | $121,650106 claims |
| AbbVieLinzess, Restasis | $178 | $119,123208 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $20 | $75,840164 claims |
| Viiv Healthcare CompanyJuluca | $23 | $71,29331 claims |
| Acadia Pharmaceuticals IncNuplazid | $29 | $70,23521 claims |
| NovartisEntresto | $41 | $25,88685 claims |
| Lilly USA, LLCTrulicity | $155 | $24,57523 claims |
| BayerKerendia | $17 | $23,84622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in Los Angeles
- Wayne ChenLos Angeles$2M
- Arman HekmatiLos Angeles$14K
- Dong LeeLos Angeles$7K
- Sylvia CarlisleLos Angeles$4K
- Joshua ChodoshLos Angeles$4K
- Azmy GhalyLos Angeles$4K
- Jo Ann PullenLos Angeles$3K
- Paul AisenSan Diego$15.7M
- Kanagaratnam SivalingamLancaster$2.4M
- Robert FeldmanLaguna Hills$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.